Page 268 - 2021_04-Haematologica-web

1184
Letters to the Editor
A
B
C
D
Figure 1. Progression-free survival and response to therapy in the different treatment arms in patients divided by age group. (A-C) Kaplan-Meier analysis of progression-free survival in the isatuximab plus pomalidine and dexamethasone treatment arm versus the pomalidine and dexamethasone treat- ment arm in patients ≥75 years (A), 65-74 years (B), and <65 years (C), as assessed by an inde- pendent response assessment committee. The hazard ratios and corresponding 95% confidence intervals are from a Cox proportional hazard model. (D) Overall response rate by age group as assessed by an independent response assessment commit- tee using the International Myeloma Working Group uniform response criteria for evaluating response in patients with multiple myeloma. A stratified Cochran-Mantel-Haenszel c2 test measured treat- ment differences in overall response rates, rates of very good partial response or better, and rates of complete response or better. PFS: progression-free survival; Isa: isatuximab; Pd: pomalidomide and dexamethasone; ORR: overall response rate; PR: partial response; VGPR: very good partial response; CR: complete response; sCR: stringent complete response.
haematologica | 2021; 106(4)